A research conducted at the Tel Aviv University has identified key molecular biomarkers that can help in early diagnosis of preeclampsia. The research has added an important dimension to the field of gynecology wherein preeclampsia is the leading cause of maternal mortality. Preeclampsia is a complication arising during pregnancy wherein the flow of blood to the placenta is blocked. The complication can also lead to interference with blood flow to the fetus, thus, leading to prematurity, low birth weight, and even death. The instance of preeclampsia is expected to occur in up to 8% of the pregnant women during their second or third trimester. If the disorder is diagnosed at an early stage, it can be easily controlled by administering aspirin during the period between the 16th week to the end of pregnancy.
Analysis of Blood Samples
Medical practitioners had been analyzing previous pregnancies, blood pressure levels, and other symptoms to gauge the risk of preeclampsia. However, with this research, they sought to find specific biomarkers in the blood that could be assessed even before any symptoms appeared. The findings of the research are suggestive of a simple blood test that could help the doctors to diagnose preeclampsia and effectuate treatment during the first trimester itself. The researchers analyzed blood samples of thousands of pregnant woman over a course of six years. The number of samples was narrowed down to 75; 35 from woman who eventually did contract preeclampsia, and 40 from women who completed healthy pregnancy tenures.
Reducing Maternal Mortality
There is optimism about reducing maternal mortality through the new research findings. This is because early testing or prediction of preeclampsia can substantially help towards curing the contraction.